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ABSTRACT: This study explores the synthesis of cyclic cis-vicinal phenyl ethylenes from oxotriphenylhexanoates. The reaction is a
BBr3-promoted cyclization of 1,6-ketoesters (1) to five-membered diketo compounds (2). The synthesis is interesting as it
constitutes one of the few examples of modular stereoselective synthesis of structures with a cis-oriented vicinal diphenylethylene.
The core structure of 2 can be smoothly derivatized, which makes it a promising synthetic building block for further stereoselective
synthetic applications.
■ INTRODUCTION
Cyclic compounds possessing adjacent C(sp3)−aryl moieties
are widely present in nature. While in most cases these
compounds have a trans-vic-diphenylethylene moiety such as
indanone1−7 and reservatrol-based natural products,8−19 the
cis-vic-diphenylethylene motif has been explored less. Never-
theless, these interesting substances still show biological
activity, and representative examples include both pharma-
ceuticals20 and natural products (Figure 1a).21−34 For example,
the rocaglates, rocaglamide, and silvestrol have received
widespread attention as they have been investigated for
therapeutic targets such as cancer21,34,35 and recently viruses
like the coronavirus,36 the Ebola virus,37 and the hepatitis E
virus.38 Thus, synthetic strategies leading to the formation the
cis-vic-diphenylethylene are attractive. However, there are only
a limited number of general methods for direct stereoselective
formation of cyclic compounds possessing the cis-vic-diphenyl-
ethylene moiety. It is also worth noting that a majority of these
syntheses are devoted to the diphenyl dihydrobenzofuran
moiety found in the rocaglates.21,23,24,34,39−51
A practical way to prepare the cis-vic-configured C(sp3)−aryl
could potentially be a ring closure of an acyclic starting
material with a preset configuration on the carbons bearing the
aryl substituents. We envisioned that a Dieckmann type
condensation of a 1,6-ketoester such as the oxotriphenylhex-
anoate (OTHO)52−56 would be ideal for this type of
transformation. The OTHO has an enolizable ketone and an
ester moiety and can, after cyclization, generate a five-
membered diketo compound. Furthermore, one very interest-
ing feature of the OTHO is that the synthesis of the OTHO
proceeds with exclusive formation of the trans-vic-diphenyl-
ethylene. Used as a starting material in the Dieckmann
condensation would thus ensure total control of the cis-vic-
diphenylethylene buildup (Figure 1b).
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Figure 1. (a) Examples of biologically active compounds with a cis-
oriented diphenylethylene moiety. (b) Design approach for the
synthesis of the desired carbocycle.
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■ RESULTS AND DISCUSSION
Our studies commenced with screening of different Lewis acids
for the cyclization of 1a (Table 1) because Lewis acids were
already reported to be useful promoters in the Dieckmann type
cyclization.57 Initial attempts showed that the cyclization
reaction was highly dependent on the Lewis acid used. Only
BBr3 and BCl3 delivered the corresponding cyclized product 2a
in good yield after 24 and 48 h, respectively (Table 1, entries 2
and 3, respectively). Single-crystal X-ray analysis of compound
2a confirmed that the vicinal aromatic rings were in the cis
orientation (Table 2, entry 2a). Other Lewis acids failed even
after prolonged reaction times (Table 1, entries 1 and 4−9).
Generally basic conditions were not efficient in promoting the
cyclization; only NaH in THF as a solvent successfully afforded
2a in 45% yield (Table1, entry 10). Investigating the loading of
BBr3 showed that 1.5 equiv of BBr3 is sufficient to reach full
conversion within 3 h and produce a yield of 80% (Table 1,
entry 11). Higher loadings of BBr3 (2−3 equiv) resulted in a
significant decrease in the level of formation of 2a, and the
polycyclization reaction of 1a afforded tricyclic compound 3
(Table 1, entries 12 and 13).58 At substoichiometric loadings
of BBr3, the cyclization reaction does not proceed efficiently.
For instance, in the presence of 0.25 equiv of BBr3, the reaction
reaches 25% conversion and stops (Table 1, entry 14). The
reaction performs best in chlorinated solvents such as
dichloromethane and chloroform; additionally, toluene is
shown to promote the reaction efficiently (Table 1, entries
11, 15, and 16).
With our optimized conditions in hand, we first decided to
verify the effectiveness of the reaction on a larger scale. It was
shown that the reaction of 1a on a 1 mmol scale proceeds with
only small decrease in the yield and the corresponding
compound 2a could be isolated in 76% yield. Next, we turned
our attention to the scope of the reaction (Table 2). The effect
of aromatic ring 3 (Ar3) on the course of cyclization was
investigated first. This revealed that the reaction tolerates a
broad scope of substituents. For example, OTHOs substituted
with halogens in the para position delivered the corresponding
products 2b−d in good yields (81−90%). Similarly, OTHOs
with a sterically demanding bromine in the meta and ortho
positions on Ar3 could also be employed in the cyclization
reaction. However, a decrease in the yield could be observed
for compounds 2e and 2f (69% and 67%, respectively)
compared to that para-substituted derivative 2d (81%).
Substrates with an electron rich Ar3 are tolerated by the
reaction, as well. For instance, OTHO with a methyl group at
the para position on Ar3 provides the corresponding product
2g in high yield (90%). A slight decrease in the yield was
observed when OTHO substituted with methyl groups at both
Ar2 and Ar3 was used. Corresponding derivative 2h was










1 BF3·OEt2 (1.0 equiv) DCM 168 0 0/0
2 BBr3 (1.0 equiv) DCM 24 100 67/0
3 BCl3 (1.0 equiv) DCM 48 100 60/0
4 AgOAc (1.0 equiv) DCM 168 0 −
5 SnCl4 (1.0 equiv) DCM 168 0 −
6 TiCl4 (1.0 equiv) DCM 168 0 −
7 AlCl3 (4.0 equiv) DCM 168 0 −
8 FeCl3 (4.0 equiv) DCM 168 0 −
9 (C6F5)3B (1.0 equiv) DCM 168 0 −
10 NaH (1.5 equiv) THF 6 50 45
11 BBr3 (1.5 equiv) DCM 3 100 80/0
12 BBr3 (2.0 equiv) DCM 5 100 30/21
13 BBr3 (3.0 equiv) DCM 5 100 11/28
14 BBr3 (0.25 equiv) DCM 168 25 15/0
15 BBr3 (1.5 equiv) CHCl3 20 100 50/0
16 BBr3 (1.5 equiv) toluene 16 100 63/0
aReactions were carried out on a 0.25 mmol scale of 1a in DCM (3
mL) in a sealed reaction vessel at room temperature. bIsolated yield.
Table 2. Substrates in BBr3-Promoted Intramolecular
Cyclization of 1a−sa
aReactions were carried out on a 0.25 mmol scale of 1 in DCM (3
mL) in a sealed reaction vessel at room temperature. b1 mmol
reaction scale.
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isolated in a good yield (76%). Introduction of a methoxy
group at the para position of Ar3 decreased the yield of the
corresponding product 2i to 50%. The lower yield can be
explained by the formation of a demethylated OTHO (1i′) as
a side product in 25% yield. The influence of a strong electron-
withdrawing group was also verified, and BBr3 applied on
OTHO substituted with a methyl ester group at the para
position of Ar3 led to the formation of product 2j in 50% yield.
Next, we investigated the effect of aromatic ring 2 (Ar2) in the
cyclization reaction. The results showed lower reactivity
compared to that of OTHOs substituted at Ar3. This was
demonstrated on OTHOs substituted with chlorine or
bromine at the para position on Ar2 where the corresponding
diketones 2k and 2l could be isolated in 59% and 72% yields,
respectively. OTHO substituted with a methyl at the para
position of Ar2 led to the formation of 2m; however, the
isolated yield was lower (70%) than that of derivative 2g
(90%). Also, the effect of the electron-withdrawing cyano
group at the para position of OTHO on Ar2 was successfully
investigated, isolating the corresponding product 2n in 79%
yield. Finally, substituent effects at Ar1 of the OTHOs were
investigated. Both p-chloro and p-bromo are well tolerated, and
the corresponding diketones 2o and 2p were isolated in good
yields (56−75%). A comparable result was obtained with
OTHO substituted with a methyl group yielding derivative 2q
in 58% yield. In addition, OTHOs substituted with electron-
withdrawing methyl ester and cyano groups at the para
position on Ar1 were successfully employed in the cyclization
reaction; however, the yields of corresponding compounds 2r
and 2s were lower (41% and 60%, respectively) than those of
derivatives 2j and 2n. Notably, the ester group and the cyano
group can be readily transferred to carboxylic acid and amide
or amine, respectively, and thus, these substrates open up for
the preparation of potentially biologically active compounds
with hydrogen bond donor and acceptor capabilities.
Expanding the scope by replacing the aryl moieties with an
alkyl group is difficult as the synthesis of 1 is not compatible
with alkyl substituents.
Mechanistically, we propose that the reaction starts with
enolization of OTHO 1 promoted by BBr3 leading to
intermediate I (Scheme 1). In the next step, the ester carbonyl
is intramolecularly activated by boron leading to the boron-
tethered species (II). In intermediate II, the enol reacts with
the ester in an intramolecular fashion, resulting in boron-
containing cyclic transition intermediate III.59 At the end of
the reaction, an excess of isopropanol is added to quench
intermediate III, generating compound 2, which is stabilized in
the enol form.
To demonstrate the versatility of this methodology, we used
2a as a building block in various transformations (Scheme 2).
At first, we focused on bromination reactions. When 2a was
subjected to N-bromosuccinimide,60 α-bromo derivative 5 was
isolated in 84% yield as a single diastereoisomer. Interestingly,
when 2a was treated with pyridinium tribromide, δ-brominated
regioisomer 4 was isolated in high yield (97%). This
bromination strategy offers a route toward compounds that
can be used as building blocks in, for example, the Reformatsky
type cyanation reaction mediated by samarium salts61 or in
organocatalytic cyclopropanation reactions.62 Remarkably,
compound 4 was like derivative 5 isolated as a single
diastereoisomer with an anti orientation of bromine and
both aromatic rings. This relative configuration of substituents
on the cyclopentanone ring was confirmed by X-ray diffraction
of both derivatives 4 and 5 (see the Supporting Information).
Apart from bromination, we also showed that 2a can be
regioselectively substituted with phenylselenium on either C-2
or C-5 of cyclopentanone based on the used conditions. When
2a was subjected to N-(phenylseleno)phthalimide in the
presence of 2 equiv of LDA, prepared in situ, selenylated
product 11 was isolated in 76% yield as a single
diastereoisomer, whereas selenylation with N-(phenylseleno)-
phthalimide without a base led to the selenylation on C-2 of
2a. The corresponding intermediate was unstable upon
isolation, but after the crude mixture had been treated with
hydrogen peroxide, the elimination reaction took place and
unsaturated derivative 6 was isolated in 70% overall yield. The
same reaction conditions were also used on compound 11.
Unfortunately, elimination did not proceed, and decomposi-
tion of the starting material was observed. On the contrary,
corresponding unsaturated derivative 12 was isolated in good
yield (85%) after treatment of 4 with 1,4-diazabicyclo[2.2.2]-
Scheme 1. Proposed Mechanism of Intramolecular
Cyclization of OTHOs (1) to Diketo Compounds 2
Scheme 2. Synthetic Transformation of 2a into Different
Derivatives 4−12a
aConditions: (a) pyridinium tribromide, DCM, rt; (b) NBS, DCM,
rt; c) N-(phenylseleno)phthalimide; DCM, rt; (d) H2O2, EtAOc, rt;
(e) m-CPBA, NaHCO3, DCM, rt; (f) N2H4, EtOH, reflux; (g)
K2CO3, MeI, DMF, 60 °C; (h) DIPA, n-BuLi, benzophenone, 0 °C to
rt; (i) DIPA, n-BuLi, N-(phenylseleno)phthalimide, DCM, 0 °C to rt;
(j) DABCO, THF, rt.
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octane (DABCO) in THF at room temperature. Furthermore,
diastereoselective hydroxylation of 2a was developed in the
presence of m-CPBA and hydroxylated diketone 7 could be
isolated in 45% yield. Next, the possibility of C−C bond
formation on C-2 and C-5 of 2a was investigated. When 2a was
treated with iodomethane in the presence of potassium
carbonate, methylated product 9 was isolated as a single
diastereoisomer in a good yield of 70%, however, as a mixture
of regioisomers (4:1 keto:enol). On the contrary, when 2 equiv
of in situ-generated LDA was used in the presence of 2a and
benzophenone as an electrophile,63 the corresponding product
10 was isolated in 65% yield as a single diastereomer. These
examples nicely illustrate the influence of both cis-oriented
aromatic rings on stereoselective addition of electrophiles to
both C-2 and C-5 to the unhindered side of the cyclic keto
ester. We were also able to show that 2a can be transformed
into pyrazole derivative 8 upon being treated with hydrazine
hydrate in ethanol under reflux conditions.64
To validate whether our diastereoselective synthesis of cis-
vic-diphenylethylene dicarbonyl compounds could be useful for
the synthesis of compounds that are structurally similar to
rocaglamide or silvestrol, a superimposition was made between
compound 2t and rocaglamide. As it turns out, the super-
imposition shows an unambiguous match between both cis-
oriented neighboring Ar of 2t and the rocaglamide aromatic
rings (Figure 2). This provides evidence that the geometry of
the diphenylethylene moiety found in the series of compound
2 mimics the diphenylethylene found in natural products such
as rocaglamide and silvestrol.
■ CONCLUSION
We have developed an intramolecular cyclization reaction of
1,6-ketoesters using boron tribromide as a Lewis acid
promoter. This methodology provides straightforward access
to 1,3-diketo compounds with a cyclopentane moiety having a
cis-oriented vicinal diphenylethylene that is unique and difficult
to obtain by known synthetic methods. We have also shown
that the defined orientation of both vicinal aromatic rings has a
directing effect on stereoselectivity in subsequent substitution
reactions with bromine, selenium, or a carbon electrophile on
C-2 or C-5 of the 1,3-diketones (Scheme 2). Also,
regioselective elimination procedures were developed on the
basis of the substitution at C-2 or C-5 providing access to two
types of α,β-unsaturated carbonyl compounds. Moreover,
successful transformation of a 1,3-diketo compound to a
heterocyclic pyrazole derivative has been demonstrated
showing the importance of 1,3-diketones as potential building
blocks for druglike architectures. Additionally, the matching
superimposition of 2t and rocaglamide indicates that the
substructure found in compound 2 is a good starting point for
the synthesis of a molecular library for probing biological
activity. Compounds including cis-vic-diphenylethylene-ori-
ented motifs such as rocaglamide and silverstrol have attracted
considerable pharmaceutical interest, e.g., in cancer treatment
and as antiviral agents.21,36−38 The synthesis protocol
presented here can easily be fine-tuned to achieve a wanted
pharmacological profile and thus opens up new opportunities
to further explore new analogues for the therapies mentioned
above.
■ EXPERIMENTAL SECTION
Molecular Modeling. To verify the hypothesis that the aromatic
rings in 2t can mimic the corresponding rings in rocaglamide,
molecular mechanics calculations were used. A conformational search
was performed on both compounds using the Amber10:EHT force
field, the Born aqueous solvation model, and the LowModeMD
search methodology. The standard settings were applied, and the
energy cutoff was set to 5 kcal/mol from their global minima. An
ensemble of conformations of the two compounds (24 of rocaglamide
and 14 of 2t) was achieved, and these were crosswise superimposed
(336 combinations). The conclusion was that superimposition of 2t
mimics rocaglamide very well, and among the top-scoring
combinations were the global minima of rocaglamide and a low-
energy conformation of 2t, i.e., ΔE = 0 and 0.7 kcal mol−1 (Figure 2).
The superimposition queries were aromatic rings 2 and 3, the
methoxy oxygen, and C-3 and C-4 in the five-membered ring (see
Scheme 2 for numbering). All molecular calculations were performed
using tools implemented in MOE modeling software.65
General Experimental Information. Column chromatography
was performed on automated column chromatography Biotage Isolera
Spektra One with Biotage SNAP-10g KP-sil columns. Thin layer
chromatography (TLC) was performed on Merck TLC plates
precoated with silica gel 60 F254 (Art 5715, 0.25 mm) and visualized
with ultraviolet light (254 nm). The 1H NMR (400 MHz) and 13C
NMR (101 MHz) spectra were recorded on a Varian 400 instrument,
and 19F NMR (470 MHz) spectra were recorded on a Varian 500
spectrometer. The chemical shifts are reported in parts per million (δ)
relative to the residual solvent peak CDCl3:
1H NMR at δ 7.26 and
13C NMR at δ 77.16. Coupling constants (J) are reported in hertz.
Infrared (IR) spectra were recorded on a PerkinElmer series FT-IR
spectrometer and are reported in wavenumbers (cm−1). Melting
points were recorded on a Stuart Scientific Melting Point SMP1
instrument. Gas chromatographic studies were performed using an
Agilent 7820A instrument equipped with a flame ionization detector
and an Agilent HP-5 19091J-413 column. Crystallographic data were
obtained using a Bruker D8 VENTURE Kappa Duo PHOTONIII
instrument. The 1-ethyl-3-methylimidazolium acetate (EMIMAc) was
purchased from Sigma-Aldrich (Stockholm, Sweden), produced by
BASF ≥95%, and dried in vacuo with heating prior to use. All other
solvents and reagents were purchased from commercial sources and
used without further treatments.
Synthesis of the Starting Material, OTHOs (1). OTHOs 1a−d, 1g,
1i−l, 1n, 1o, 1e, 1f, 1h, 1m, and 1p−s were synthesized according to
previously published procedures.52,58
Figure 2. Superimposition of the global minima conformation of
rocaglamide (green) and a low-energy conformation (ΔE = 0.7 kcal
mol−1) of 2t (orange).
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Methyl 4-(4-Cyanophenyl)-6-oxo-3,4-diphenylhexanoate (1n).
Isolated as a white solid (450 mg, 53% yield); mp 167−169 °C
(from MeOH); 1H NMR (400 MHz, CDCl3) δ 7.67−7.57 (m, 4H),
7.52−7.42 (m, 3H), 7.39−7.22 (m, 7H), 3.70 (td, J = 10.8 Hz, J′ =
3.2 Hz, 1H), 3.48−3.39 (s, 4H), 3.28 (dd, J = 17.2 Hz, J′ = 10.5 Hz,
1H), 2.96 (dd, J = 17.3 Hz, J′ = 3.2 Hz, 1H), 2.50 (dd, J = 15.6 Hz, J′
= 10.2 Hz, 1H), 2.34 (dd, J = 15.6 Hz, J′ = 4.5 Hz, 1H); 13C{1H}
NMR (101 MHz, CDCl3) δ 197.8, 172.2, 148.4, 141.3, 136.7, 133.3,
132.6 (2C), 129.4 (2C), 129.1 (2C), 128.7 (2C), 128.2 (2C), 127.9
(2C), 127.6, 118.9, 111.0, 51.7, 47.4, 46.7, 43.4, 39.8; ATR-FTIR ν
2951, 2228, 1726, 1718, 1679, 1609, 1597, 1436, 1237, 1157 cm−1;
HRMS (ESI) m/z calcd for C26H24NO3 [M + H]
+ 398.1751, found
398.1751.
General Procedure for the BBr3-Promoted Synthesis of 2. To a
flask equipped with a magnetic stir bar were added OTHO 1a−s
(0.25 mmol, 1 equiv) and DCM (3 mL). The solution was stirred at
room temperature under nitrogen and syringed with a solution of
BBr3 (375 μL, 1 M in DCM, 1.5 equiv). The mixture was stirred until
full conversion was reached (monitored by TLC), then the reaction
quenched with i-PrOH (2 mL), and the mixture evaporated to
dryness. The crude material was separated by flash chromatography
with a petroleum ether/EtOAc mixture, yielding the corresponding
compound 2a−s.
Procedure for the BBr3-Promoted Synthesis of 2a on a 1 mmol
Scale. To a flask equipped with a magnetic stir bar were added
OTHO 1a (0.372 mmol, 1 equiv) and DCM (12 mL). The solution
was stirred at room temperature under nitrogen and syringed with a
solution of BBr3 (1.5 mL, 1 M in DCM, 1.5 equiv). The mixture was
stirred until full conversion was reached (monitored by TLC), then
the reaction quenched with i-PrOH (8 mL), and the mixture
evaporated to dryness. The crude material was separated by flash
chromatography in a petroleum ether/EtOAc mixture yielding
corresponding compound 2a as a yellow solid (204 mg, 76%).
(2Z)-2-[Hydroxy(phenyl)methylidene]-3,4-diphenylcyclopentan-
1-one (2a). Purified in 92:8 petroleum ether/EtOAc; 68 mg yield as a
yellow solid (80%); mp 121−123 °C (from MeOH); 1:10 keto:enol.
Enol: 1H NMR (400 MHz, CDCl3) δ 7.55−7.49 (m, 2H), 7.40−7.34
(m, 1H), 7.28−7.24 (m, 3H), 7.12−7.06 (m, 6H), 6.78−6.74 (m,
3H), 4.36 (d, J = 7.4 Hz, 1H), 3.87 (dt, J = 14.0 Hz, J′ = 7.2 Hz, 1H),
3.09 (dd, J = 17.4 Hz, J′ = 13.5 Hz, 1H), 2.62 (dd, J = 17.3 Hz, J′ =
7.1 Hz, 1H); 13C{1H} NMR (101 MHz, CDCl3) δ 209.3, 170.8,
140.5, 138.9, 133.9, 131.2, 128.6 (2C), 128.4 (2C), 128.3 (2C), 128.2
(4C), 127.9 (2C), 126.8, 126.7, 113.3, 52.0, 48.3, 39.8. Keto: 1H
NMR (400 MHz, CDCl3) δ 8.04−7.96 (m, 2H), 7.62−7.56 (m, 1H),
7.50−7.48 (m, 2H), 7.17−7.13 (m, 3H), 7.11−7.06 (m, 3H), 6.82−
6.76 (m, 4H), 4.83 (d, J = 8.3 Hz, 1H), 4.57−4.44 (m, 1H), 4.07 (q, J
= 7.0 Hz, 1H), 3.01−2.92 (m, 2H); 13C{1H} NMR (101 MHz,
CDCl3) δ 212.3, 194.5, 139.6, 138.6, 136.6, 133.7, 129.6, 128.7 (2C),
128.3 (2C), 128.2 (3C), 128.1 (4C), 127.0, 126.9, 61.2, 51.1, 45.5,
44.8; ATR-FTIR ν 1758, 1642, 1608, 1593, 1570, 1357, 1268, 1222,




nylcyclopentan-1-one (2b). Purified in 99:1 to 97:3 petroleum
ether/EtOAc; 81 mg yield as a thick orange oil (90%); 1:10 keto:enol.
Enol: 1H NMR (400 MHz, CDCl3) δ 7.55−7.51 (m, 2H), 7.41−7.34
(m, 1H), 7.26 (s, 2H), 7.17−7.09 (m, 3H), 6.83−6.66 (m, 6H), 4.33
(d, J = 7.4 Hz, 1H), 3.85 (dt, J = 14.0 Hz, J′ = 7.2 Hz, 1H), 3.02 (dd, J
= 17.3 Hz, J′ = 13.5 Hz, 1H), 2.62 (dd, J = 17.3 Hz, J′ = 7.1 Hz, 1H);
13C{1H} NMR (101 MHz, CDCl3) δ 208.9, 171.1, 161.7 (d, J = 245.2
Hz), 140.4, 134.7 (d, J = 3.1 Hz), 133.9, 131.3, 129.6 (d, J = 8.0 Hz,
2C), 128.6 (2C), 128.4 (6C), 126.9, 114.8 (d, J = 21.2 Hz, 2C),
113.1, 52.0, 47.6, 40.1; 19F NMR (470 MHz, CDCl3) δ −115.9 (ddd,
J = 13.7 Hz, J′ = 8.3 Hz, J″ = 5.4 Hz). Keto: 1H NMR (400 MHz,
CDCl3) δ 8.07−7.96 (m, 2H), 7.62−7.57 (m, 1H), 7.50−7.45 (m,
2H), 7.28−7.24 (m, 1H), 7.17−7.09 (m, 2H), 6.88−6.74 (m, 6H),
4.82 (d, J = 7.7 Hz, 1H), 4.46 (t, J = 7.3 Hz, 1H), 4.08 (q, J = 7.2 Hz,
1H), 2.93 (d, J = 7.8 Hz, 2H); 13C{1H} NMR (101 MHz, CDCl3) δ
212.0, 194.4, 161.8 (d, J = 245.6 Hz), 138.6, 136.4, 135.3 (d, J = 3.3
Hz), 133.9, 133.9, 129.7 (2C), 129.5 (d, J = 8.0 Hz, 2C), 128.8 (2C),
128.2 (2C), 127.2, 115.1 (d, J = 21.2 Hz, 2C), 61.4, 51.1, 44.9, 44.6;
19F NMR (470 MHz, CDCl3) δ −115.8 (tt, J = 8.5 Hz, J′ = 5.5 Hz);
ATR-FTIR ν 2905, 1746, 1636, 1592, 1565, 1510, 1492, 1448, 1352,
1219, 1150, 1096 cm−1; HRMS (ESI) m/z calcd for C24H20FO2 [M +
H]+ 359.1442, found 359.1437.
(2Z)-4-(4-Chlorophenyl)-2-[hydroxy(phenyl)methylidene]-3-phe-
nylcyclopentan-1-one (2c). Purified in 98:2 to 97:3 petroleum ether/
EtOAc; 74 mg yield as a thick orange oil (80%); 1:10 keto:enol. Enol:
1H NMR (400 MHz, CDCl3) δ 7.57−7.47 (m, 2H), 7.43−7.34 (m,
1H), 7.26 (s, 2H), 7.18−7.11 (m, 3H), 7.09−7.02 (m, 2H), 6.82−
6.76 (m, 2H), 6.67 (d, J = 8.4 Hz, 2H), 4.34 (d, J = 7.4 Hz, 1H), 3.83
(dt, J = 14.0 Hz, J′ = 7.2 Hz, 1H), 3.03 (dd, J = 17.3 Hz, J′ = 13.4 Hz,
1H), 2.61 (dd, J = 17.3 Hz, J′ = 7.1 Hz, 1H); 13C{1H} NMR (101
MHz, CDCl3) δ 208.7, 171.1, 140.3, 137.6, 133.9, 132.5, 131.4, 129.5
(2C), 128.6 (2C), 128.5 (2C), 128.4 (4C), 128.1 (2C), 127.0, 113.1,
51.8, 47.7, 39.9. Keto: 1H NMR (400 MHz, CDCl3) δ 8.02 (dd, J =
8.4 Hz, J′ = 1.3 Hz, 2H), 7.64−7.55 (m, 1H), 7.50−7.46 (m, 2H),
7.28−7.24 (m, 3H), 7.16−7.10 (m, 4H), 6.82−6.76 (m, 2H), 6.76−
6.71 (m, 2H), 4.82 (d, J = 7.6 Hz, 1H), 4.47 (t, J = 7.3 Hz, 1H), 4.08
(q, J = 7.3 Hz, 1H), 2.92 (d, J = 7.6 Hz, 2H); 13C{1H} NMR (101
MHz, CDCl3) δ 211.8, 194.3, 138.4, 138.1, 136.4, 132.7, 131.4, 129.7
(2C), 129.4 (2C), 128.8 (2C), 128.5 (2C), 128.3 (2C), 128.2 (2C),
127.3, 61.5, 51.0, 45.0, 44.4; ATR-FTIR ν 3026, 1743, 1595, 1570,
1493, 1447, 1362, 1266, 1226, 1091, 1016 cm−1; HRMS (ESI) m/z
calcd for C24H20ClO2 [M + H]
+ 375.1146, found 375.1160.
(2Z)-4-(4-Bromophenyl)-2-[hydroxy(phenyl)methylidene]-3-phe-
nylcyclopentan-1-one (2d). Purified in 98:2 to 97:3 petroleum
ether/EtOAc; 85 mg yield as a thick orange oil (81%); 1:10 keto:enol.
Enol: 1H NMR (400 MHz, CDCl3) δ 7.55−7.49 (m, 2H), 7.42−7.35
(m, 1H), 7.29−7.19 (m, 4H), 7.17−7.10 (m, 3H), 6.81−6.77 (m,
2H), 6.65−6.57 (m, 2H), 4.35 (d, J = 7.4 Hz, 1H), 3.81 (dt, J = 14.0
Hz, J′ = 7.2 Hz, 1H), 3.02 (dd, J = 17.3 Hz, J′ = 13.5 Hz, 1H), 2.61
(dd, J = 17.3 Hz, J′ = 7.1 Hz, 1H); 13C{1H} NMR (101 MHz,
CDCl3) δ 208.7, 171.1, 140.2, 138.1, 133.9, 131.3, 131.0 (2C), 129.9
(2C), 128.6 (2C), 128.5 (2C), 128.4 (4C), 127.0, 120.7, 113.1, 51.8,
47.8, 39.9. Keto: 1H NMR (400 MHz, CDCl3) δ 8.07−7.99 (m, 2H),
7.62−7.57 (m, 1H), 7.50−7.46 (m, 1H), 7.26 (s, 1H), 7.17−7.09 (m,
4H), 6.82−6.75 (m, 2H), 6.68 (d, J = 8.4 Hz, 2H), 4.82 (d, J = 7.6
Hz, 1H), 4.47 (t, J = 7.3 Hz, 1H), 4.06 (q, J = 7.3 Hz, 1H), 2.95−2.89
(m, 2H); 13C{1H} NMR (101 MHz, CDCl3) δ 211.7, 194.2, 138.6,
138.4, 136.4, 133.9, 131.3 (2C), 129.7 (4C), 128.8 (2C), 128.5 (2C),
128.1 (2C), 127.3, 120.8, 61.4, 50.9, 45.1, 44.3; ATR-FTIR ν 3028,
1746, 1596, 1567, 1490, 1365, 1263, 1225, 1077, 1011 cm−1; HRMS




nylcyclopentan-1-one (2e). Purified in 97:3 to 95:5 petroleum ether/
EtOAc; 72 mg yield as a thick orange oil (69%); 1:10 keto:enol. Enol:
1H NMR (400 MHz, CDCl3) δ 7.56−7.51 (m, 2H), 7.42−7.35 (m,
1H), 7.30−7.22 (m, 3H), 7.16−7.13 (m, 3H), 6.96−6.89 (m, 2H),
6.81−6.77 (m, 2H), 6.67−6.63 (m, 1H), 4.35 (d, J = 7.4 Hz, 1H),
3.81 (dt, J = 14.1 Hz, J′ = 7.3 Hz, 1H), 3.03 (dd, J = 17.3 Hz, J′ = 13.4
Hz, 1H), 2.62 (dd, J = 17.3 Hz, J′ = 7.2 Hz, 1H); 13C{1H} NMR (101
MHz, CDCl3) δ 208.5, 171.2, 141.5, 140.2, 133.8, 131.5, 131.4, 129.9,
129.5, 128.5 (2C), 128.4 (6C), 127.1, 126.7, 122.1, 113.0, 51.9, 48.0,
39.7. Keto: 1H NMR (400 MHz, CDCl3) δ 8.06−8.00 (m, 2H),
7.62−7.57 (m, 1H), 7.51−7.47 (m, 1H), 7.29−7.22 (m, 3H), 7.16−
7.13 (m, 3H), 7.03−6.99 (m, 1H), 6.83−6.77 (m, 2H), 6.76−6.72
(m, 1H), 4.82 (d, J = 7.1 Hz, 1H), 4.46 (t, J = 7.1 Hz, 1H), 4.08 (q, J
= 7.4 Hz, 1H), 2.92 (dd, J = 7.8 Hz, J′ = 1.1 Hz, 1H); 13C{1H} NMR
(101 MHz, CDCl3) δ 211.6, 194.2, 141.9, 138.4, 136.3, 133.9, 131.3,
130.0, 129.7 (3C), 128.8 (2C), 128.4 (2C), 128.1 (2C), 127.4, 126.5,
122.4, 61.7, 51.0, 45.3, 43.9; ATR-FTIR ν 3024, 2917, 1744, 1637,
1592, 1569, 1494, 1475, 1357, 1265, 1225, 1152, 1098, 1075 cm−1;




nylcyclopentan-1-one (2f). Purified in 97:3 to 95:5 petroleum ether/
EtOAc; 70 mg yield as a thick orange oil (67%); 1:24 keto:enol; 1H
NMR (400 MHz, CDCl3) δ 7.62−7.49 (m, 3H), 7.42−7.34 (m, 1H),
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7.30−7.26 (m, 2H), 7.12−7.04 (m, 3H), 6.99−6.94 (m, 1H), 6.92−
6.79 (m, 3H), 6.41 (dd, J = 7.9 Hz, J′ = 1.7 Hz, 1H), 4.73 (d, J = 7.4
Hz, 1H), 4.29 (dt, J = 14.1 Hz, J′ = 7.2 Hz, 1H), 3.13 (dd, J = 17.2
Hz, J′ = 13.7 Hz, 1H), 2.59 (dd, J = 17.2 Hz, J′ = 7.1 Hz, 1H);
13C{1H} NMR (101 MHz, CDCl3) δ 208.4, 171.5, 140.8, 138.0,
133.9, 132.7, 131.4, 128.5 (2C), 128.4 (5C), 128.3, 128.0 (2C),
126.9, 126.8, 125.5, 112.6, 48.4, 47.1, 39.1; ATR-FTIR ν 3067, 3024,
1596, 1567, 1494, 1471, 1367, 1230, 1023 cm−1; HRMS (ESI) m/z
calcd for C24H20BrO2 [M + H]
+ 419.0641, found 419.0630.
(2Z)-2-[Hydroxy(phenyl)methylidene]-4-(4-methylphenyl)-3-
phenylcyclopentan-1-one (2g). Purified in 98:2 to 97:3 petroleum
ether/EtOAc; 80 mg yield as a thick yellow oil (90%); 1:7 keto:enol.
Enol: 1H NMR (400 MHz, CDCl3) δ 7.57−7.54 (m, 2H), 7.40−7.35
(m, 1H), 7.29−7.26 (m, 2H), 7.14−7.11 (m, 3H), 6.93−6.91 (m,
2H), 6.85−6.78 (m, 2H), 6.67−6.65 (m, 2H), 4.36 (d, J = 7.4 Hz,
1H), 3.84 (dt, J = 14.1 Hz, J′ = 7.2 Hz, 1H), 3.08 (dd, J = 17.3 Hz, J′
= 13.6 Hz, 1H), 2.61 (dd, J = 17.3 Hz, J′ = 7.1 Hz, 1H), 2.27 (s, 3H);
13C{1H} NMR (101 MHz, CDCl3) δ 209.5, 170.7, 140.6, 136.3,
135.8, 134.0, 131.2, 128.7 (2C), 128.6 (2C), 128.4 (2C), 128.3 (2C),
128.2 (2C), 128.1 (2C), 126.7, 113.4, 51.9, 48.1, 40.1, 21.1. Keto: 1H
NMR (400 MHz, CDCl3) δ 8.05−8.00 (m, 2H), 7.52−7.48 (m, 2H),
7.30−7.26 (m, 2H), 7.15−7.08 (m, 3H), 7.00−6.96 (m, 2H), 6.84−
6.78 (m, 1H), 6.72 (d, J = 8.1 Hz, 2H), 4.86 (d, J = 8.6 Hz, 1H), 4.51
(dd, J = 8.6 Hz, J′ = 6.8 Hz, 1H), 4.05 (q, J = 6.9 Hz, 1H), 2.96 (d, J =
6.9 Hz, 1H), 2.27 (s, 3H); 13C{1H} NMR (101 MHz, CDCl3) δ
212.5, 194.6, 172.1, 142.2, 138.7, 136.4, 134.0, 133.7, 129.6, 128.9
(2C), 128.7 (2C), 128.6 (2C), 128.2 (2C), 128.0 (2C), 127.9 (2C),
61.1, 51.9, 45.1, 22.0; ATR-FTIR ν 3024, 1744, 1608, 1592, 1571,
1515, 1492, 1448, 1365, 1261, 1227, 1150, 1098, 1078, 1030 cm−1;




cyclopentan-1-one (2h). Purified in 98:2 petroleum ether/EtOAc; 70
mg yield as a thick yellow oil (76%); 1:5 keto:enol. Enol: 1H NMR
(400 MHz, CDCl3) δ 7.58−7.51 (m, 2H), 7.40−7.33 (m, 1H), 7.28−
7.25 (m, 2H), 6.91 (d, J = 7.8 Hz, 4H), 6.71−6.61 (m, 4H), 4.29 (d, J
= 7.2 Hz, 1H), 3.79 (dt, J = 14.0 Hz, J′ = 7.1 Hz, 1H), 3.04 (dd, J =
17.3 Hz, J′ = 13.7 Hz, 1H), 2.57 (dd, J = 17.3 Hz, J′ = 7.0 Hz, 1H),
2.26 (s, 6H); 13C{1H} NMR (101 MHz, CDCl3) δ 209.7, 170.4,
137.4, 136.3 (2C), 136.2, 136.0, 131.2, 129.0 (2C), 128.6 (2C), 128.6
(2C), 128.5 (2C), 128.3 (2C), 128.2 (2C), 113.8, 51.5, 48.2, 40.1,
21.2 (2C). Keto: 1H NMR (400 MHz, CDCl3) δ 8.02−7.96 (m, 2H),
7.59−7.55 (m, 1H), 7.51−7.42 (m, 3H), 7.29−7.24 (m, 2H), 6.97 (d,
J = 7.8 Hz, 2H), 6.74−6.68 (m, 3H), 4.79 (d, J = 8.5 Hz, 1H), 4.43
(dd, J = 8.5 Hz, J′ = 6.8 Hz, 1H), 4.00 (q, J = 6.9 Hz, 1H), 2.93 (d, J =
6.9 Hz, 2H), 2.26 (s, 6H); 13C{1H} NMR (101 MHz, CDCl3) δ
212.8, 194.8, 136.7, 136.6, 136.5, 136.4, 135.6, 133.7, 129.6 (2C),
128.9 (4C), 128.7 (2C), 128.1 (4C), 61.4, 50.8, 45.2, 45.1, 21.1 (2C);
ATR-FTIR ν 3020, 2913, 1744, 1573, 1513, 1494, 1361, 1223 cm−1;




phenylcyclopentan-1-one (2i). Purified in 98:2 petroleum ether/
EtOAc; 46 mg yield as a thick yellow oil (50%); 1:5 keto:enol. Enol:
1H NMR (400 MHz, CDCl3) δ 7.61−7.51 (m, 2H), 7.39−7.33 (m,
1H), 7.28−7.24 (m, 2H), 7.15−7.06 (m, 3H), 6.82−6.75 (m, 2H),
6.65−6.63 (m, 3H), 4.32 (d, J = 7.4 Hz, 1H), 3.82 (dt, J = 14.0 Hz, J′
= 7.2 Hz, 1H), 3.73 (s, 3H), 3.02 (dd, J = 17.3 Hz, J′ = 13.6 Hz, 1H),
2.59 (dd, J = 17.3 Hz, J′ = 7.1 Hz, 1H); 13C{1H} NMR (101 MHz,
CDCl3) δ 209.5, 170.7, 158.4, 140.7, 134.0, 131.2, 129.6, 129.2 (2C),
128.7 (2C), 128.4 (2C), 128.3 (4C), 126.7, 113.6, 113.4 (2C), 55.3,
52.0, 47.7, 40.2. Keto: 1H NMR (400 MHz, CDCl3) δ 8.04−7.96 (m,
2H), 7.61−7.56 (m, 1H), 7.50−7.45 (m, 2H), 7.14−7.09 (m, 3H),
6.82−6.75 (m, 2H), 6.70 (d, J = 2.8 Hz, 2H), 6.64 (d, J = 3.2 Hz,
2H), 4.81 (d, J = 8.5 Hz, 0H), 4.46 (dd, J = 8.4, 6.8 Hz, 1H), 4.02 (q,
J = 6.9 Hz, 1H), 3.75 (s, 2H), 2.96−2.90 (m, 1H); 13C{1H} NMR
(101 MHz, CDCl3) δ 212.6, 195.0, 138.8, 136.6, 133.8, 131.6, 131.0
(2C), 129.6, 129.1 (2C), 128.8 (2C), 128.3 (4C), 127.0, 113.4 (2C),
61.2, 56.3, 51.2, 45.1, 44.8; ATR-FTIR ν 2840, 1744, 1610, 1515,
1365, 1248, 1180, 1032 cm−1; HRMS (ESI) m/z calcd for C25H23O3
[M + H]+ 371.1642, found 371.1638.
Characterization of Demethylated OTHO (1i′). Methyl 4-(4-
Hydroxyphenyl)-6-oxo-3,4-diphenylhexanoate (1i′). Purified in 3:1
pentane/EtAOc; 25 mg yield (25%) as a white solid; mp 180−182 °C
(from MeOH); 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 7.6 Hz,
2H), 7.45 (t, J = 7.3 Hz, 1H), 7.34−7.27 (m, 6H), 7.21−7.12 (m,
3H), 6.72 (d, J = 7.7 Hz, 2H), 3.55 (td, J = 11.3 Hz, J′ = 10.2 Hz, J″ =
6.6 Hz, 1H), 3.47−3.21 (m, 5H), 2.93 (dd, J = 16.6 Hz, J′ = 3.2 Hz,
1H), 2.67−2.30 (m, 2H); 13C{1H} NMR (101 MHz, CDCl3) δ 199.3,
173.2, 155.0, 142.6, 137.1, 133.8, 133.0, 129.4 (2C), 128.8 (2C),
128.5 (2C), 128.4 (2C), 128.0 (2C), 127.0, 115.8 (2C), 51.7, 47.3
(2C), 44.0, 40.3; ATR-FTIR ν 2204, 2160, 2190, 1726, 1680, 1514,




phenylcyclopentyl}benzoate (2j). Purified in 94:6 to 93:7 petroleum
ether/EtOAc; 50 mg yield as a thick yellow oil (50%); 1:8 keto:enol
1:8. Enol: 1H NMR (400 MHz, CDCl3) δ 7.79−7.73 (m, 2H), 7.53−
7.50 (m, 2H), 7.39−7.35 (m, 1H), 7.28−7.24 (s, 3H), 7.13−7.05 (m,
3H), 6.87−6.81 (m, 2H), 6.78−6.75 (m, 2H), 4.39 (d, J = 7.4 Hz,
1H), 3.96−3.86 (m, 4H), 3.11 (dd, J = 17.3 Hz, J′ = 13.4 Hz, 1H),
2.64 (dd, J = 17.4 Hz, J′ = 7.1 Hz, 1H); 13C{1H} NMR (101 MHz,
CDCl3) δ 208.6, 171.3, 167.0, 144.6, 140.2, 133.9, 131.4, 129.3 (2C),
128.5 (4C), 128.4 (5C), 128.2 (2C), 127.0, 113.0, 52.1, 51.9, 48.3,
39.6. Keto: 1H NMR (400 MHz, CDCl3) δ 8.02 (dt, J = 9.0 Hz, J′ =
1.5 Hz, 2H), 8.00−7.94 (m, 2H), 7.82−7.79 (m, 2H), 7.62−7.57 (m,
1H), 7.51−7.47 (m, 2H), 7.13−7.03 (m, 2H), 6.94−6.86 (m, 2H),
6.78−6.75 (m, 2H), 4.83 (d, J = 7.5 Hz, 1H), 4.51 (t, J = 7.3 Hz, 1H),
4.16 (q, J = 7.3 Hz, 1H), 3.87 (s, 3H), 3.05−2.92 (m, 2H); 13C{1H}
NMR (101 MHz, CDCl3) δ 211.6, 194.2, 145.0, 138.3, 136.3, 130.0,
129.7 (2C), 129.5 (2C), 128.8 (2C), 128.6 (3C), 128.1 (4C), 127.3,
61.6, 51.0, 45.6, 44.1, 35.3, 31.0; ATR-FTIR ν 3062, 2951, 1717,
1677, 1607, 1570, 1493, 1367, 1277, 1097, 1019 cm−1; HRMS (ESI)
m/z calcd for C26H23O4 [M + H]
+ 399.1591, found 399.1607.
(2Z)-3-(4-Chlorophenyl)-2-[hydroxy(phenyl)methylidene]-4-phe-
nylcyclopentan-1-one (2k). Purified in 99:1 to 95:5 petroleum ether/
EtOAc; 55 mg yield as a thick transparent oil (59%); 1:4 keto:enol.
Enol: 1H NMR (400 MHz, CDCl3) δ 7.52−7.44 (m, 2H), 7.42−7.35
(m, 1H), 7.30−7.26 (m, 1H), 7.22−7.16 (m, 1H), 7.16−7.09 (m,
3H), 7.09−7.02 (m, 2H), 6.85−6.74 (m, 2H), 6.74−6.64 (m, 2H),
4.35 (d, J = 7.4 Hz, 1H), 3.93−3.82 (m, 1H), 3.09−2.94 (m, 1H),
2.67−2.57 (m, 1H); 13C{1H} NMR (101 MHz, CDCl3) δ 212.1,
171.7, 139.5, 138.9, 131.8, 130.2 (2C), 130.0, 128.8 (2C), 128.7
(2C), 128.6 (2C), 128.5 (4C), 128.4, 127.4, 113.2, 51.7, 48.5, 39.9.
Keto: 1H NMR (400 MHz, CDCl3) δ 8.01−7.96 (m, 2H), 7.62−7.56
(m, 1H), 7.52−7.44 (m, 1H), 7.30−7.26 (m, 1H), 7.22−7.16 (m,
2H), 7.16−7.09 (m, 3H), 6.85−6.74 (m, 2H), 6.74−6.64 (m, 2H),
4.76 (d, J = 9.1 Hz, 1H), 4.56−4.47 (m, 1H), 4.06−3.99 (q, J = 6.7
Hz, 1H), 3.09−2.94 (m, 1H); 13C{1H} NMR (101 MHz, CDCl3) δ
212.1, 194.5, 139.7, 137.5, 134.2, 134.2, 132.9, 130.0, 129.8, 129.1,
128.8, 128.8 (2C), 128.7(2C), 128.6 (2C), 128.4 (2C), 127.5, 61.3,
50.7, 45.6, 45.4; ATR-FTIR ν 2956, 2915, 1546, 1566, 1489, 1351,
1257, 1227, 1088, 1014 cm−1; HRMS (ESI) m/z calcd for
C24H20ClO2 [M + H]
+ 375.1146, found 375.1145.
(2Z)-3-(4-Bromophenyl)-2-[hydroxy(phenyl)methylidene]-4-phe-
nylcyclopentan-1-one (2l). Purified in 99:1 to 97:3 petroleum ether/
EtOAc; 75 mg yield as a thick yellow oil (72%); 1:10 keto:enol. Enol:
1H NMR (400 MHz, CDCl3) δ 7.54−7.46 (m, 2H), 7.44−7.36 (m,
1H), 7.29−7.25 (m, 2H), 7.24−7.19 (m, 2H), 7.16−7.10 (m, 3H),
6.82−6.74 (m, 2H), 6.69−6.58 (m, 2H), 4.34 (d, J = 7.4 Hz, 1H),
3.94−3.81 (m, 1H), 3.04 (dd, J = 17.4 Hz, J′ = 13.5 Hz, 1H), 2.63
(dd, J = 17.4 Hz, J′ = 7.1 Hz, 1H); 13C{1H} NMR (101 MHz,
CDCl3) δ 208.9, 171.3, 139.6, 138.5, 133.8, 131.4, 131.3 (2C), 130.2
(2C), 128.4 (2C), 128.3 (2C), 128.2 (2C), 128.1 (2C), 127.1, 120.7,
112.7, 51.4, 48.1, 39.5. Keto: 1H NMR (400 MHz, CDCl3) δ 8.04−
7.97 (m, 2H), 7.64−7.56 (m, 1H), 7.53−7.45 (m, 1H), 7.30−7.24
(m, 1H), 7.24−7.18 (m, 2H), 7.16−7.11 (m, 3H), 6.84−6.79 (s, 2H),
6.68−6.62 (m, 2H), 4.77 (d, J = 9.2 Hz, 1H), 4.51 (dd, J = 9.2 Hz, J′
= 6.9 Hz, 1H), 4.03 (q, J = 6.7 Hz, 1H), 2.97 (d, J = 6.6 Hz, 1H);
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13C{1H} NMR (101 MHz, CDCl3) δ 211.6, 194.1, 139.3, 137.7,
136.5, 133.9, 131.3, 129.8 (2C), 129.6 (2C), 128.8 (2C), 128.4 (2C),
128.1 (2C), 127.1 (2C), 121.0, 60.8, 50.4, 45.2, 45.0; ATR-FTIR ν
2959, 1742, 1644, 1592, 1565, 1486, 1351, 1230 cm−1; HRMS (ESI)
m/z calcd for C24H20BrO2 [M + H]
+ 419.0641, found 419.0641.
(2Z)-2-[Hydroxy(phenyl)methylidene]-3-(4-methylphenyl)-4-
phenylcyclopentan-1-one (2m). Purified in 98:2 to 97:3 petroleum
ether/EtOAc; 62 mg yield as a thick yellow oil (70%); 1:10 keto:enol.
Enol: 1H NMR (400 MHz, CDCl3) δ 7.61−7.54 (m, 2H), 7.43−7.34
(m, 1H), 7.30−7.26 (s, 2H), 7.16−7.07 (m, 3H), 6.95−6.89 (m, 2H),
6.84−6.76 (m, 2H), 6.71−6.64 (m, 2H), 4.35 (d, J = 7.3 Hz, 1H),
3.85 (dt, J = 14.0 Hz, J′ = 7.1 Hz, 1H), 3.10 (dd, J = 17.3 Hz, J′ = 13.7
Hz, 1H), 2.62 (dd, J = 17.2 Hz, J′ = 7.0 Hz, 1H), 2.26 (s, 3H);
13C{1H} NMR (101 MHz, CDCl3) δ 209.5, 170.5, 139.0, 137.3,
136.2, 134.0, 131.2, 128.9 (2C), 128.5 (2C), 128.4 (2C), 128.3 (2C),
128.2 (2C), 127.9 (2C), 126.7, 113.6, 51.6, 48.4, 39.8, 21.1. Keto: 1H
NMR (400 MHz, CDCl3) δ 8.07−7.99 (m, 2H), 7.52−7.45 (m, 2H),
7.30−7.26 (s, 2H), 7.20−7.17 (m, 3H), 6.95−6.89 (m, 1H), 6.88−
6.82 (m, 2H), 6.72−6.62 (m, 2H), 4.83 (d, J = 8.3 Hz, 1H), 4.48 (dd,
J = 8.3 Hz, J′ = 6.9 Hz, 1H), 4.07 (q, J = 7.0 Hz, 1H), 3.02−2.91 (m,
2H), 2.24 (s, 3H); 13C{1H} NMR (101 MHz, CDCl3) δ 212.5, 194.7,
139.7, 136.6, 136.5, 135.5, 133.7, 129.6 (2C), 128.9 (2C), 128.7
(2C), 128.2 (2C), 128.1 (2C), 128.0 (2C), 126.8, 61.4, 50.8, 45.5,
44.8, 21.1; ATR-FTIR ν 2917, 1740, 1606, 1569, 1494, 1369, 1265




phenylcyclopentyl}benzonitrile (2n). Purified in 9:1 to 4:1 pentane/
EtOAc; 72 mg yield as a thick pink oil (79%); >1:7 keto:enol. Enol:
1H NMR (400 MHz, CDCl3) δ 7.48−7.41 (m, 2H), 7.36 (dd, J = 9.5
Hz, J′ = 7.8 Hz, 3H), 7.28−7.24 (m, 2H), 7.12 (dt, J = 5.4 Hz, J′ = 2.7
Hz, 3H), 6.87 (d, J = 8.1 Hz, 2H), 6.76 (dd, J = 7.1 Hz, J′ = 2.4 Hz,
2H), 4.48 (d, J = 7.6 Hz, 1H), 3.95 (dt, J = 12.9 Hz, J′ = 7.4 Hz, 1H),
3.03 (dd, J = 17.5 Hz, J′ = 13.0 Hz, 1H), 2.69 (dd, J = 17.5 Hz, J′ =
7.2 Hz, 1H); 13C{1H} NMR (101 MHz, CDCl3) δ 208.2, 172.2,
146.4, 138.1, 133.6, 131.9 (2C), 131.6, 129.1 (2C), 128.6, 128.4
(2C), 128.3 (2C), 128.1 (2C), 127.9 (2C), 127.3, 111.9, 110.6, 52.0,
47.9, 39.4. Keto: 1H NMR (400 MHz, CDCl3) δ 8.06−7.97 (m, 2H),
7.61 (t, J = 7.4 Hz, 1H), 7.50 (t, J = 7.7 Hz, 2H), 7.21−7.17 (m, 3H),
6.89−6.86 (m, 3H), 6.81−6.78 (m, 3H), 4.82 (d, J = 9.6 Hz, 1H),
4.64 (dd, J = 9.6 Hz, J′ = 6.9 Hz, 1H), 4.06 (td, J = 7.1 Hz, J′ = 5.1
Hz, 1H), 3.06−2.96 (m, 2H); 13C{1H} NMR (101 MHz, CDCl3) δ
210.7, 193.5, 144.3, 139.0, 136.3, 134.0, 132.0 (2C), 129.7 (2C),
128.9, 128.8 (2C), 128.6 (2C), 128.4 (2C), 128.3 (2C), 127.4, 118.8,
110.9, 60.2, 50.7, 45.1; ATR-FTIR ν 3029, 2228, 1743, 1607, 1570,
1493, 1361, 1227, 1151 cm−1; HRMS (ESI) m/z calcd for
C25H20NO2 [M + H]
+ 366.1489, found 366.1489.
(2Z)-2-[Hydroxy(4-methylphenyl)methylidene]-3,4-diphenylcy-
clopentan-1-one (2o). Purified in 99:1 to 95:5 petroleum ether/
EtOAc; 52 mg yield as a thick transparent oil (56%); >1:20 keto:enol.
Enol: 1H NMR (400 MHz, CDCl3) δ 7.51−7.45 (m, 2H), 7.27−7.21
(m, 2H), 7.17−7.04 (m, 6H), 6.80−6.73 (m, 4H), 4.33 (d, J = 7.4 Hz,
1H), 3.94−3.83 (m, 1H), 3.59−3.03 (m, 1H), 2.68−2.59 (m, 1H);
13C{1H} NMR (101 MHz, CDCl3) δ 212.6, 212.3, 209.7, 193.5,
169.9, 140.7, 140.6, 139.8, 139.1, 138.8, 137.8, 135.2, 132.7, 131.4,
130.1, 129.4, 129.0, 128.9, 128.7, 128.5, 128.3, 127.4, 127.2, 113.4,
77.2, 61.6, 52.3, 48.6, 45.8, 45.2, 40.1; ATR-FTIR ν 3027, 1591, 1487,
1360, 1259, 1090, 1011 cm−1; HRMS (ESI) m/z calcd for
C24H20ClO2 [M + H]
+ 375.1139, found 375.1146.
(2Z)-2-[(4-Bromophenyl)(hydroxy)methylidene]-3,4-diphenylcy-
clopentan-1-one (2p). Purified in 98:2 to 96:4 petroleum ether/
EtOAc; 79 mg yield as a thick yellow oil (75%); 1:18 keto:enol. Enol:
1H NMR (400 MHz, CDCl3) δ 7.42−7.38 (m, 4H), 7.14−7.06 (m,
6H), 6.81−6.72 (m, 4H), 4.33 (d, J = 7.4 Hz, 1H), 3.88 (dt, J = 14.1
Hz, J′ = 7.3 Hz, 1H), 3.10 (dd, J = 17.4 Hz, J′ = 13.6 Hz, 1H), 2.64
(dd, J = 17.4 Hz, J′ = 7.1 Hz, 1H); 13C{1H} NMR (101 MHz,
CDCl3) δ 209.4, 169.6, 140.2, 138.7, 132.8, 131.6 (2C), 129.9 (2C),
128.5 (2C), 128.4 (2C), 128.2 (2C), 128.0 (2C), 126.9, 126.9, 126.0,
113.5, 51.9, 48.2, 39.8. Keto: 1H NMR (400 MHz, CDCl3) δ 7.89 (d,
J = 8.7 Hz, 2H), 7.62 (d, J = 8.5 Hz, 2H), 7.56−7.52 (m, 1H), 7.35−
7.29 (m, 1H), 7.18−7.07 (m, 6H), 6.84−6.73 (m, 2H), 4.77 (d, J =
8.4 Hz, 1H), 4.52 (dd, J = 8.6 Hz, J′ = 6.9 Hz, 1H), 4.06 (q, J = 7.0
Hz, 1H), 3.01−2.94 (m, 2H); 13C{1H} NMR (101 MHz, CDCl3) δ
211.9, 193.3, 139.4, 138.5, 135.3, 132.1 (2C), 131.2 (2C), 128.3
(2C), 128.2 (2C), 128.1 (4C), 127.1, 127.0, 126.0, 61.2, 50.9, 45.4,
44.8; ATR-FTIR ν 1588, 1485, 1359, 1257, 1234, 1071, 1007 cm−1;




clopentan-1-one (2q). Purified in 99:1 to 95:5 petroleum ether/
EtOAc; 51 mg yield as a thick transparent oil (58%); 1:10 keto:enol.
Enol: 1H NMR (400 MHz, CDCl3) δ 7.49−7.44 (m, 2H), 7.14−7.05
(m, 8H), 6.85−6.69 (m, 4H), 4.38 (d, J = 7.4 Hz, 1H), 3.87 (dt, J =
13.6 Hz, J′ = 7.2 Hz, 1H), 3.09 (dd, J = 17.3 Hz, J′ = 13.6 Hz, 1H),
2.62 (dd, J = 17.3 Hz, J′ = 7.1 Hz, 1H), 2.32 (s, 3H); 13C{1H} NMR
(101 MHz, CDCl3) δ 209.0, 171.2, 141.9, 140.6, 139.0, 131.1, 129.1
(2C), 128.6 (2C), 128.5 (2C), 128.2 (4C), 128.0 (2C), 126.8, 126.7,
112.8, 52.1, 48.4, 39.7, 21.6. Keto: 1H NMR (400 MHz, CDCl3) δ
7.93 (d, J = 8.3 Hz, 2H), 7.28 (dt, J = 8.0 Hz, J′ = 0.8 Hz, 3H), 7.18−
7.14 (m, 3H), 7.11−7.04 (m, 2H), 6.90−6.88 (m, 2H), 6.83−6.81
(m, 4H), 4.82 (d, J = 8.2 Hz, 1H), 4.51 (dd, J = 8.2 Hz, J′ = 7.0 Hz,
1H), 4.08 (q, J = 7.0 Hz, 1H), 3.01−2.91 (m, 1H), 2.42 (s, 3H);
13C{1H} NMR (101 MHz, CDCl3) δ 212.5, 194.0, 144.8, 139.7,
138.8, 134.1, 129.8 (2C), 129.5 (2C), 128.2 (6C), 128.1 (2C), 127.0,
126.9, 61.2, 51.1, 45.5, 44.7 21.8; ATR-FTIR ν 3022, 1744, 1632,
1595, 1495, 1364, 1225, 1149, 1098 cm−1; HRMS (ESI) m/z calcd
for C25H23O2 [M + H]
+ 355.1693, found 355.1698.
Methyl 4-{Hydroxy[(1Z)-5-oxo-2,3-diphenylcyclopentylidene]-
methyl}benzoate (2r). Purified in 99:1 to 95:5 petroleum ether/
EtOAc; 41 mg yield as a thick transparent oil (41%); >1:20 keto:enol.
Enol: 1H NMR (400 MHz, CDCl3) δ 8.06−7.77 (m, 2H), 7.68−7.48
(m, 2H), 7.16−7.00 (m, 6H), 6.82−6.69 (m, 4H), 4.34 (d, J = 7.4 Hz,
1H), 3.88 (s, 3H), 3.10 (dd, J = 17.5 Hz, J′ = 13.5 Hz, 1H), 2.65 (dd,
J = 17.4 Hz, J′ = 7.1 Hz, 1H); 13C{1H} NMR (101 MHz, CDCl3) δ
209.9, 169.2, 166.4, 140.3, 138.7, 138.0, 132.1, 129.5 (2C), 128.6
(2C), 128.4 (2C), 128.3 (2C), 128.2 (2C), 128.0 (2C), 126.9, 114.3,
77.2, 52.5, 51.9, 48.2, 39.9; ATR-FTIR ν 2957, 1712, 1636, 1593,
1426, 1371, 1283, 1112, 1018 cm−1; HRMS (ESI) m/z calcd for
C26H23O4 [M + H]
+ 399.1591, found 399.1597.
4-{Hydroxy[(1Z)-5-oxo-2,3-diphenylcyclopentylidene]methyl}-
benzonitrile (2s). Purified in 9:1 to 4:1 pentane/EtOAc; 55 mg yield
as an orange solid (60%); mp 122−125 °C; >1:10 keto:enol. Enol: 1H
NMR (400 MHz, CDCl3) δ 7.61 (d, J = 8.5 Hz, 2H), 7.53 (d, J = 8.5
Hz, 2H), 7.15−7.05 (m, 6H), 6.75 (td, J = 7.5 Hz, J′ = 2.0 Hz, 4H),
4.32 (d, J = 7.4 Hz, 1H), 3.89 (dt, J = 13.0 Hz, J′ = 7.2 Hz, 1H), 3.10
(dd, J = 17.5 Hz, J′ = 13.4 Hz, 1H), 2.67 (dd, J = 17.5 Hz, J′ = 7.1 Hz,
1H); 13C{1H} NMR (101 MHz, CDCl3) δ 210.1, 167.7, 139.9, 138.4,
138.1, 132.0 (2C), 128.8 (2C), 128.5 (2C), 128.4 (2C), 128.1 (4C),
127.1, 127.0, 114.7, 114.4 (2C), 51.7, 48.1, 39.9. Keto: 1H NMR (400
MHz, CDCl3) δ 8.10 (d, J = 8.2 Hz, 2H), 7.78 (d, J = 8.2 Hz, 2H),
7.18−7.13 (m, 6H), 6.84−6.74 (m, 4H), 4.79 (d, J = 8.9 Hz, 1H),
4.53 (dd, J = 8.9 Hz, J′ = 6.9 Hz, 1H), 4.05 (q, J = 6.8 Hz, 1H), 2.99
(dd, J = 6.7 Hz, J′ = 4.6 Hz, 2H); 13C{1H} NMR (101 MHz, CDCl3)
δ 211.4, 193.1, 139.5, 139.2, 138.2, 132.5 (2C), 130.0 (2C), 128.3
(4C), 128.0 (4C), 127.2, 127.1, 116.9, 114.4, 61.5, 50.8, 45.4, 45.0;
ATR-FTIR ν 3030, 1637, 1585, 1495, 1345, 1261, 1224, 1148, cm−1;




nylcyclopentan-1-one (2t). Purified in 8:1 to 4:1 pentane/EtOAc; 43
mg yield as a yellow semisolid (46%); >1:10 keto:enol. Enol: 1H
NMR (400 MHz, CDCl3) δ 7.55−7.53 (m, 2H), 7.41−7.33 (m, 1H),
7.31−7.22 (m, 2H), 7.14−7.05 (m, 3H), 6.79−6.76 (m, 2H), 6.72−
6.59 (m, 4H), 4.31 (d, J = 7.2 Hz, 1H), 3.89−3.78 (m, 1H), 3.73 (s,
3H), 3.06 (dd, J = 17.3 Hz, J′ = 13.6 Hz, 1H), 2.60 (dd, J = 17.3 Hz,
J′ = 7.0 Hz, 1H); 13C{1H} (101 MHz, CDCl3) δ 209.5, 170.7, 158.4,
139.1, 132.6, 131.3, 129.6 (3C), 128.5 (2C), 128.4 (2C), 128.3 (2C),
128.0 (2C), 126.8, 113.7 (2C), 113.6, 55.3, 51.2, 48.4, 39.8. Keto: 1H
NMR (400 MHz, CDCl3) δ 8.00−7.98 (m, 1H), 7.49−7.46 (m, 3H),
7.26−7.24 (m, 2H), 7.18−7.15 (m, 3H), 6.84−6.80 (m, 2H), 6.72−
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6.62 (m, 4H), 4.76 (d, J = 8.4 Hz, 1H), 4.44 (dd, J = 8.4 Hz, J′ = 6.9
Hz, 1H), 4.02 (q, J = 6.8 Hz, 1H), 3.71 (s, 3H), 2.98−2.91 (m, 2H);
13C{1H} NMR (101 MHz, CDCl3) δ 212.6, 194.8, 139.8, 136.7,
133.8, 130.7, 129.6 (2C), 129.2 (2C), 128.8 (2C), 128.4, 128.3 (2C),
128.2 (2C), 128.0, 126.9, 113.7 (2C), 61.6, 50.5, 45.5, 44.9; ATR-
FTIR ν 2934, 1741, 1608, 1570, 1509, 1246 cm−1; HRMS (ESI) m/z
calcd for C25H22O3Na [M + Na]
+ 393.1461, found 393.1467.
Bromination of 2a with Pyridinium Tribromide. Diketo
compound 2a (210 mg, 0.62 mmol, 1 equiv) was dissolved in
DCM (18 mL) and cooled to 0 °C. Then PyrHBr·Br2 (220 mg, 90%,
0.62 mmol, 1 equiv) was added at once while the reaction mixture was
vigorously stirred. The reaction mixture was then stirred overnight at
room temperature. A saturated solution of NaHCO3 was added; the
organic phase was extracted and washed with water and dried, and the
solvent was removed in vacuo. The crude mixture was purified by
automated column chromatography with a 98:2 petroleum ether/
EtOAc eluent, yielding product 4 as a pale orange solid.
(5Z)-2-Bromo-5-[hydroxy(phenyl)methylidene]-3,4-diphenylcy-
clopentan-1-one (4). Yield 250 mg (97%); mp 120−122 °C (from
MeOH); >1:20 keto:enol; 1H NMR (400 MHz, CDCl3) δ 7.58−7.52
(m, 2H), 7.45−7.38 (m, 1H), 7.30−7.26 (m, 2H), 7.20−7.09 (m,
6H), 6.77−6.74 (m, 4H), 5.22 (dd, J = 12.3 Hz, J′ = 1.2 Hz, 1H), 4.43
(d, J = 7.6 Hz, 1H), 3.99 (dd, J = 12.3 Hz, J′ = 7.6 Hz, 1H); 13C{1H}
NMR (101 MHz, CDCl3) δ 200.8, 173.2, 139.5, 136.0, 133.1, 131.9,
128.6 (2C), 128.5 (4C), 128.3 (2C), 128.2 (4C), 127.4, 127.2, 110.3,
58.4, 52.3, 51.2; ATR-FTIR ν 3058, 1637, 1591, 1567, 1491, 1447,
1356, 1142, 1076 cm−1; HRMS (ESI) m/z calcd for C24H20BrO2 [M
+ H]+ 419.0641, found 419.0635.
Bromination of 2a with N-Bromosuccinimide. According to the
published procedure,52 a solution of NBS (26 mg, 0.15 mmol, 1
equiv) in DCM (2 mL) was added to a solution of 1,3-diketone 2a
(50 mg, 0.15 mmol, 1 equiv) at rt. The reaction mixture was allowed
to stir at room temperature for 6 h until full conversion was achieved.
Then the reaction mixture was directly purified by automated column
chromatography with a petroleum ether/EtOAc gradient (98:2 to
97:3), yielding the desired compound 5 as a single diastereoisomer as
an off-white oil that was crystallized from methanol to give a pale off-
white solid.
2-Benzoyl-2-bromo-3,4-diphenylcyclopentan-1-one (5). Yield 52
mg (84%); mp 112−115 °C (from MeOH); 1H NMR (400 MHz,
CDCl3) δ 7.93−7.82 (m, 2H), 7.45−7.36 (m, 1H), 7.30−7.26 (s,
2H), 7.11−7.08 (m, 3H), 6.98−6.81 (m, 5H), 6.64−6.56 (m, 2H),
4.64−4.52 (m, 1H), 4.41 (dd, J = 6.5 Hz, J′ = 1.3 Hz, 1H), 3.11 (dd, J
= 19.1 Hz, J′ = 13.3 Hz, 1H), 2.92 (ddd, J = 19.1 Hz, J′ = 7.9 Hz, J″ =
1.4 Hz, 1H); 13C{1H} NMR (101 MHz, CDCl3) δ 204.4, 190.9,
137.2, 135.5, 135.1, 132.9, 129.4, 129.1, 128.2, 128.0, 127.9, 127.4,
127.1, 77.2, 63.3, 61.6, 42.6, 39.1; ATR-FTIR ν 3029, 1757, 1664,
1596, 1447, 1252, 1234, 1142, 1072 cm−1; HRMS (ESI) m/z calcd
for C24H20BrO2 [M + H]
+ 419.0641, found 419.0631.
Synthesis of 6. To diketo compound 2a (60 mg, 0.176 mmol, 1
equiv) in DCM (3 mL) was added at rt a solution of N-
(phenylseleno)phthalimide (90 mg, 90%, 0.26 mmol, 1.5 equiv).
The reaction mixture stirred for 3 h until full conversion was achieved,
and the solvent was removed in vacuo. The crude mixture was then
dissolved in EtOAc (6 mL), and hydrogen peroxide (2 mL of 30% in
water) was added. After 3 h, full conversion was achieved, the reaction
mixture was diluted with water (1 mL), and the organic phase was
collected and washed with saturated NaHCO3 and water and dried
over MgSO4. After filtration and evaporation of the solvent, the crude
product was separated by automated column chromatography with a
petroleum ether/EtOAc gradient (93:7 to 85:15), yielding product 6
as a transparent oil.
2-Benzoyl-3,4-diphenylcyclopent-2-en-1-one (6). Yield 42 mg
(70%); 1H NMR (400 MHz, CDCl3) δ 7.94−7.84 (m, 1H), 7.59−
7.49 (m, 1H), 7.44−7.40 (m, 2H), 7.31−7.13 (m, 10H), 4.80 (dd, J =
7.4 Hz, J′ = 2.3 Hz, 1H), 3.30 (dd, J = 19.0 Hz, J′ = 7.4 Hz, 1H), 2.67
(dd, J = 19.0 Hz, J′ = 2.3 Hz, 1H); 13C{1H} NMR (101 MHz,
CDCl3) δ 204.2, 194.6, 172.8, 141.5, 136.1, 134.4, 134.2, 130.8, 129.5
(2C), 129.3 (2C), 128.9 (2C), 128.7 (4C), 127.5 (2C), 127.3, 123.7,
47.3, 46.3; ATR-FTIR ν 3057, 1690, 1654, 1597, 1579, 1497, 1331,
1236, 1174, 1052 cm−1; HRMS (ESI) m/z calcd for C24H19O2 [M +
H]+ 339.1385, found 339.1389.
Hydroxylation of 2a. To the mixture of 2a (120 mg, 0.35 mmol, 1
equiv) and 0.5 M aqueous NaHCO3 (0.7 mL, 1 equiv) in DCM (4
mL) was added m-CPBA (198 mg, 77%, 0.88 mmol, 2.5 equiv)
portionwise at ambient temperature. After 3 h, full conversion was
achieved according to TLC analysis. The excess of peracid was
quenched by adding 15% aqueous Na2SO3 (3 mL), and the resulting
mixture was stirred for an additional 1 h at room temperature. The
organic layer was then separated, washed with brine (5 mL), dried
over MgSO4, and filtered and concentrated in vacuo. The residue was
purified by automated column chromatography with a petroleum
ether/EtOAc gradient (98:2 to 85:15), yielding product 7 as a single
diastereoisomer as a thick transparent oil.
2-Benzoyl-2-hydroxy-3,4-diphenylcyclopentan-1-one (7). Yield
56 mg (45%); 1H NMR (400 MHz, CDCl3) δ 7.94−7.63 (m, 2H),
7.42−7.34 (m, 1H), 7.27−7.19 (m, 2H), 7.15−7.04 (m, 3H), 7.00−
6.97 (m, 2H), 6.87−6.84 (m, 3H), 6.76−6.73 (m, 2H), 4.32 (dt, J =
14.3 Hz, J′ = 7.6 Hz, 1H), 4.19 (dd, J = 8.0 Hz, J′ = 1.2 Hz, 1H), 3.50
(dd, J = 17.8 Hz, J′ = 13.7 Hz, 1H), 2.95 (ddd, J = 17.8 Hz, J′ = 7.3
Hz, J″ = 1.4 Hz, 1H); 13C{1H} NMR (101 MHz, CDCl3) δ 213.5,
198.4, 138.1, 135.1, 135.1, 133.1, 130.4 (2C), 129.9 (2C), 128.2
(2C), 128.0 (4C), 127.9 (2C), 127.0, 126.7, 87.8, 60.3, 42.8, 41.6;
ATR-FTIR ν 3396, 3029, 1748, 1665, 1596, 1448, 1251, 1039 cm−1;
HRMS (ESI) m/z calcd for C24H21O3 [M + H]
+ 357.1485, found
357.1499.
Reaction of 2a with Hydrazine Hydrate. According to the
published procedure,56 to a sealed vial with 2a (168 mg, 0.49 mmol, 1
equiv) in EtOH (4 mL) was added hydrazine hydrate (37 μL, 65% in
water, 1 equiv). The reaction mixture was then heated on an oil bath
to reflux until full conversion was achieved as indicated by TLC. The
solvent was then removed in vacuo, and the reaction mixture was then
purified by automated column chromatography with a petroleum
ether/EtOAc gradient (80:20 to 67:33), yielding pyrazole derivative 8
as a yellow thick oil (110 mg, 66%).
3,4,5-Triphenyl-2H,4H,5H,6H-cyclopenta[c]pyrazole (8). Yield
110 mg (66%); 1H NMR (400 MHz, CDCl3) δ 10.19 (bs, 1H),
7.54−7.37 (m, 2H), 7.28−7.19 (m, 3H), 7.13−7.06 (m, 3H), 7.03−
6.99 (m, 3H), 6.88−6.86 (m, 2H), 6.74−6.65 (m, 2H), 4.57 (d, J =
7.8 Hz, 1H), 4.47 (dtd, J = 10.2 Hz, J′ = 7.7 Hz, J″ = 2.1 Hz, 1H),
3.24 (dd, J = 15.3 Hz, J′ = 10.9 Hz, 1H), 3.07 (ddd, J = 15.4 Hz, J′ =
7.7, J″ = 2.0 Hz, 1H); 13C{1H} NMR (101 MHz, CDCl3) δ 140.2,
140.2, 130.3, 129.0 (4C), 128.7 (2C), 128.6 (2C), 128.0 (2C), 127.9
(2C), 127.8 (2C), 126.5, 126.4, 125.8, 125.8, 58.1, 49.4, 29.1; ATR-
FTIR ν 3026, 2898, 1602, 1493, 1452, 1314, 1233, 1180, 1109 cm−1;
HRMS (ESI) m/z calcd for C24H21N2 [M + H]
+ 337.1699, found
337.1704.
Methylation of 2a. To the starting 2a (0.85 mmol, 290 mg,
1equiv) in DMF (5 mL) under argon was added K2CO3 (0.94 mmol,
180 mg, 1.5 equiv), and then methyl iodide (0.94 mmol, 60 μL, 1.1
equiv) was slowly added. The reaction mixture was then stirred
overnight at 60 °C (oil bath). The next day, the reaction was
quenched with water (5 mL) and the mixture washed with EtOAc (3
× 50 mL). The combined organic layer was washed with brine (2 ×
30 mL) and dried over MgSO4. After filtration, the solvent was
evaporated in vacuo and the crude material was separated by
automated column chromatography with a pentane/EtOAc gradient
(85:15 to 4:1), yielding product 9 as a thick transparent oil.
2-Benzoyl-2-methyl-3,4-diphenylcyclopentan-1-one and 2-
[Methoxy(phenyl)methylidene]-3,4-diphenylcyclopentan-1-one
(9a:9b). Yield 210 mg (70%); 4:1 keto:enol ether. Keto: 1H NMR
(400 MHz, CDCl3) δ 7.68−7.56 (m, 2H), 7.35−7.31 (m, 1H), 7.29−
7.19 (m, 2H), 7.13−7.05 (m, 4H), 6.94−6.87 (m, 4H), 6.77−6.75
(m, 2H), 4.15−4.11 (m, 1H), 4.08 (t, J = 6.9 Hz, 1H), 3.28 (dd, J =
18.0 Hz, J′ = 13.5 Hz, 1H), 2.73 (dd, J = 18.5 Hz, J′ = 6.2 Hz, 1H),
1.85 (s, 3H); 13C{1H} NMR (101 MHz, CDCl3) δ 214.1, 199.2,
137.9, 137.2, 136.2, 132.0, 129.5, 128.7 (2C), 128.0 (6C), 127.9
(2C), 127.6 (2C), 126.7, 65.8, 60.2, 43.2, 40.6, 24.7. Enol: 1H NMR
(400 MHz, CDCl3) δ 7.77−7.69 (m, 2H), 7.47−7.44 (m, 1H), 7.40−
7.37 (m, 2H), 7.03−6.97 (m, 3H), 6.87 (s, 4H), 4.58 (d, J = 8.2 Hz,
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1H), 4.01 (q, J = 8.8 Hz, 1H), 3.77 (s, 3H), 3.22−3.15 (m, 1H), 3.01
(dd, J = 16.8 Hz, J′ = 8.1 Hz, 1H); 13C{1H} NMR (101 MHz,
CDCl3) δ 192.4, 167.6, 140.3, 140.1, 139.7, 131.3, 128.6 (2C), 128.2
(2C), 127.7 (4C), 126.7 (4C), 126.3, 126.1, 116.2, 58.0, 54.4, 46.7,
35.3; ATR-FTIR ν 3026, 1745, 1669, 1596, 1454, 1246 cm−1; HRMS
(ESI) m/z calcd for C25H23O2 [M + H]
+ 355.1698, found 355.1700.
Aldol Reaction of 2a with Benzophenone. According to the
modified procedure,55 diisopropylamine (91 μL, 2.20 equiv) was
dissolved in dry tetrahydrofuran (5 mL), and after the mixture had
cooled to 0 °C, n-butyllithium (260 μL, 2.20 equiv, 2.5 M solution in
n-hexane) was added. The reaction mixture was stirred at rt for 30
min followed by further cooling to 0 °C. Diketone 2a (100 mg, 0.29
mmol, 1 equiv) was dissolved in dry tetrahydrofuran (3 mL) and
slowly added to the solution of diisopropylamine and n-butyllithium,
and the mixture was stirred. After 15 min, benzophenone (65 mg,
0.35 mmol, 1.20 equiv) was added and the reaction mixture stirred at
0 °C for 30 min and then at rt overnight. After 16 h, TLC revealed full
conversion; the reaction was then quenched by the addition of a
saturated aqueous solution of ammonium chloride (1 mL) and water
(10 mL), and EtAOc was then added. The organic phase was
separated, and the aqueous phase extracted with EtOAc (2 × 20 mL).
The combined organic phases were washed with brine and dried over
MgSO4, and the solvent was evaporated in vacuo. The crude material
was purified by automated column chromatography with a petroleum
ether/EtOAc gradient (95:5 to 92:8), yielding product 10 as a
transparent oil.
(2Z)-2-[Hydroxy(phenyl)methylidene]-5-(hydroxydiphenylmeth-
yl)-3,4-diphenylcyclopentan-1-one (10). Yield 100 mg (65%); >1:20
keto/enol; 1H NMR (400 MHz, CDCl3) δ 7.50 (ddd, J = 15.3 Hz, J′
= 8.2 Hz, J″ = 1.2 Hz, 4H), 7.39−7.31 (m, 1H), 7.28−7.18 (m, 6H),
7.05−6.93 (m, 5H), 6.86−6.60 (m, 5H), 6.33 (bs, 2H), 4.36 (d, J =
10.6 Hz, 1H), 4.25 (d, J = 8.2 Hz, 1H), 4.04 (dd, J = 10.6 Hz, J′ = 8.1
Hz, 1H), 3.87 (s, 1H); 13C{1H} NMR (101 MHz, CDCl3) δ 208.7,
172.9, 146.1, 143.9, 141.4, 139.5, 133.8, 131.4, 128.6 (4C), 128.2
(4C), 128.1 (2C), 127.9 (2C), 127.5 (2C), 127.3 (2C), 127.2, 127.0
(4C), 126.8, 126.5, 125.4, 113.5, 79.7, 57.7, 51.0, 50.8; ATR-FTIR ν
3061, 3028, 2956, 1738, 1603, 1568, 1492, 1447, 1365, 1269, 1218,
1154 cm−1; HRMS (ESI) m/z calcd for C37H29O3 [M − H]−
521.2117, found 521.2119.
Selenylation of 2a. According to the modified procedure,55
diisopropylamine (91 μL, 2.20 equiv) was dissolved in dry
tetrahydrofuran (5 mL). After the mixture had cooled to 0 °C, n-
butyllithium (260 μL, 2.20 equiv, 2.5 M solution in n-hexane) was
added and the reaction mixture was stirred at room temperature for
30 min. Then after the mixture had again cooled to 0 °C, diketone 2a
(100 mg, 0.29 mmol, 1 equiv) was dissolved in dry tetrahydrofuran (3
mL) and slowly added to the solution of diisopropylamine and n-
butyllithium. The reaction mixture was stirred for 15 min followed by
an addition of N-(phenylseleno)phthalimide (120 mg, 1.20 equiv);
the subsequent mixture was stirred at 0 °C for 30 min and then at rt
for an additional 60 min when, according to TLC, full conversion was
achieved. The reaction was then quenched by the addition of a
saturated aqueous solution of NH4Cl (1 mL) and water (10 mL), and
EtAOc (20 mL) was then added. The organic phase was separated,
and the aqueous phase extracted with EtOAc (2 × 20 mL). The
combined organic phases were washed with brine and dried over
MgSO4, and the solvent was evaporated in vacuo. The crude material
was purified by automated column chromatography with a petroleum
ether/EtOAc gradient (98:2 to 92:8), yielding product 11 as single
diastereoisomer in the form of a thick yellow oil.
(2Z)-2-[Hydroxy(phenyl)methyl idene]-3,4-diphenyl-5-
(phenylselanyl)cyclopentan-1-one (11). Yield 110 mg (76%) as a
thick yellow oil; 1:20 keto/enol. Enol: 1H NMR (400 MHz, CDCl3) δ
7.62−7.53 (m, 2H), 7.52−7.49 (m, 2H), 7.39−7.26 (m, 2H), 7.28−
7.18 (m, 4H), 7.14−7.01 (m, 6H), 6.75−6.68 (m, 2H), 6.67−6.59
(m, 2H), 4.42 (d, J = 12.1 Hz, 1H), 4.33 (d, J = 7.6 Hz, 1H), 3.66
(dd, J = 12.1 Hz, J′ = 7.6 Hz, 1H); 13C{1H} NMR (101 MHz,
CDCl3) δ 205.2, 172.3, 140.2, 137.6, 136.50 (2C), 133.7, 131.5, 129.0
(2C), 128.6, 128.5 (6C), 128.3 (4C), 128.0 (2C), 126.9 (2C), 126.8,
111.6, 54.5, 51.3, 50.5. Keto: 1H NMR (400 MHz, CDCl3) δ 8.10−
8.04 (m, 2H), 7.76 (dd, J = 8.2 Hz, J′ = 1.3 Hz, 1H), 7.68−7.61 (m,
4H), 7.35−7.28 (m, 2H), 7.26−7.20 (m, 2H), 7.18−7.12 (m, 3H),
7.08−7.04 (m, 2H), 6.80−6.75 (m, 4H), 4.86 (dd, J = 8.1 Hz, J′ = 1.2
Hz, 1H), 4.70 (t, J = 7.6 Hz, 1H), 4.29 (dd, J = 5.6 Hz, J′ = 1.3 Hz,
1H), 3.97−3.89 (m, 1H); 13C{1H} NMR (101 MHz, CDCl3) δ 206.9,
192.4, 136.5 (2C), 136.1 (2C), 133.7, 131.5, 130.0, 129.3, 129.0
(2C), 128.6 (2C), 128.5 (2C), 128.5 (4C), 128.3 (2C), 128.2 (2C),
127.1 (2C), 126.9, 60.6, 52.2, 48.91; ATR-FTIR ν 3059, 3028, 1719,
1604, 1592, 1568, 1493, 1360, 1260, 1221, 1150, 1071 cm−1; HRMS
(ESI) m/z calcd for C30H25O2Se [M + H]
+ 497.1014, found
497.1019.
Elimination of Brominated Diketo Compound 4. 1,4-
Diazabicyclo[2.2.2]octane (DABCO) (0.49 mmol, 55 mg, 2 equiv)
was added to a stirred solution of brominated diketone 4 (0.24 mmol,
100 mg, 1 equiv) in THF (5 mL) at rt. Full conversion was achieved
after 2 h (TLC monitoring). The reaction mixture was evaporated
and purified by automated column chromatography with a pentane/
EtOAc gradient (9:1 to 5:1), yielding product 12 as a thick orange oil.
5-Benzoyl-3,4-diphenylcyclopent-2-en-1-one (12). Yield 70 mg
(85%); >2:1 keto/enol. Keto: 1H NMR (400 MHz, CDCl3) δ 8.13−
8.01 (m, 2H), 7.66−7.57 (m, 2H), 7.55−7.44 (m, 3H), 7.41−7.24
(m, 4H), 7.25−7.16 (m, 3H), 7.00−6.89 (m, 1H), 6.69 (d, J = 1.4 Hz,
1H), 5.34 (t, J = 1.7 Hz, 1H), 4.61 (d, J = 2.0 Hz, 1H); 13C{1H}
NMR (101 MHz, CDCl3) δ 200.9, 193.2, 175.9, 141.3, 136.2, 133.7,
132.9, 131.4, 130.6, 130.2 (2C), 129.4 (2C), 128.9 (2C), 128.7 (2C),
128.4 (2C), 127.6 (2C), 126.5, 67.1, 50.4. Enol: 1H NMR (400 MHz,
CDCl3) δ 8.12−8.08 (m, 2H), 7.60−7.57 (m, 2H), 7.55−7.50 (m,
2H), 7.41−7.24 (m, 5H), 7.24−7.18 (m, 2H), 7.00−6.91 (m, 2H),
6.87 (d, J = 1.2 Hz, 0H), 5.26 (d, J = 1.3 Hz, 1H); 13C{1H} NMR
(101 MHz, CDCl3) δ 199.8, 169.9, 168.7, 138.8, 134.2, 133.2, 130.5,
128.8 (2C), 128.3 (4C), 128.1 (2C), 128.0 (2C), 127.9 (2C), 127.5
(2C), 126.8, 116.8, 50.8; ATR-FTIR ν 3060, 1690, 1666, 1596, 1570,
1493, 1446, 1176, 1148, 1000 cm−1; HRMS (ESI) m/z calcd for
C24H19O2 [M + H]
+ 339.1380, found 339.1380.
General Procedure for Sample Preparation and Crystal
Measurement. Single crystals of products 2a, 4, and 5 were prepared
by volatilization using a mixture of methanol and dichloromethane as
a solvent. Suitable crystals were selected and collected on a Bruker D8
VENTURE Kappa Duo PHOTONIII instrument by an IμS
microfocus sealed tube with Mo Kα (λ = 0.71073) (5) or Cu Kα
(λ = 1.54178 Å) (2a and 4) radiation at a low temperature of 120 K.
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